[1] Hong DS, Farago AF, Brose MS, Burris, III HA, Dowlati A, Bauer TM, Taylor M, Shaw AT, et al.Clinical safety and activity from a phase I study of LOXO-101, a selective TRKA/B/C inhibitor, in solid-tumor patients with NTRK gene fusions.Presentation Session: Clinical Trials Plenary Session, Sunday, April 17, 4:15-6 p.m. CT, La Nouvelle Orleans Ballroom. AACR 2016Abstract: CT008.
Home Hong DS, Farago AF, Brose MS
